EMA fees for human medicinal product pharmacovigilance

This procedure concerns fees charged by the European Medicines Agency (EMA) for monitoring the safety of medicines for human use once they are on the market. It aims to ensure the agency has the necessary resources for these crucial safety checks.

This affects pharmaceutical companies that market medicines in the EU. The fees will cover the costs of pharmacovigilance activities, ensuring ongoing safety monitoring and public health protection.